Patents Examined by Maher M. Haddad
  • Patent number: 11643463
    Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: May 9, 2023
    Assignee: WUXI Biologics (Shanghai) Co., Ltd.
    Inventors: Zhuozhi Wang, Jing Li, Gennady Gololobov, Jianqing Xu
  • Patent number: 11643458
    Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: May 9, 2023
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tatsuya Takahashi, Mai Yoshikawa, Sosuke Yoneda, Junji Onoda, Etsuo Nakamura, Tsuguo Miyauchi, Toshiyuki Asaki, Erika Kasai
  • Patent number: 11639377
    Abstract: The disclosure discloses a preparation of type I collagen-like fibers and a method for regulating and controlling the periodic length of fiber stripes thereof, belonging to the technical field of genetic engineering. The disclosure produces a three-segment chimeric collagen P-CL-P pattern by inserting a continuous Gly-Xaa-Yaa triplet collagen sequence in the middle based on the N- and C-terminal (GPP)n sequences. The self-assembly is driven by the interaction between the N- and C-terminal (GPP)n triple helixes to form banded fibers with periodic bright and dark stripes. According to the method of the disclosure, a fiber from a clean source, which can self-assemble to form periodic bright and dark stripes can be prepared, the structure of which is similar to type I collagen, the preparation process is simple, the collagen fiber with low cost can be produced on a large scale, and the method has broad application prospects in the field of biological materials.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: May 2, 2023
    Inventors: Fei Xu, Jinyuan Hu, Vikas Nanda, David I. Shreiber, Meng Zhang, Sonal Gahlawat
  • Patent number: 11639390
    Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 2, 2023
    Assignee: AbbVie Inc.
    Inventors: Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
  • Patent number: 11634490
    Abstract: Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 25, 2023
    Assignee: Accurus Biosciences, Inc.
    Inventors: Haishan Lin, Yi Zhang
  • Patent number: 11623956
    Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: April 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
  • Patent number: 11623962
    Abstract: The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: April 11, 2023
    Inventor: Damien Bresson
  • Patent number: 11608378
    Abstract: Antibodies that bind to ???8 are provided.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 21, 2023
    Inventors: Stephen L. Nishimura, Anthony Cormier, Saburo Ito, Jianlong Lou, James D. Marks, Yifan Cheng, Melody G. Campbell, Jody L. Baron
  • Patent number: 11596688
    Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 7, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Maria Rosario, Timothy L. Wyant, Brihad Abhyankar
  • Patent number: 11597765
    Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: March 7, 2023
    Assignees: VACCINEX, INC., The Sydney Children's Hospital Network
    Inventors: Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
  • Patent number: 11591402
    Abstract: New antibodies and methods of use are described.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: February 28, 2023
    Assignee: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Jianlong Lou, James D. Marks, Jody L. Baron, Yifan Cheng, Shenping Wu, Anthony Cormier, Naoki Takasaka
  • Patent number: 11590201
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: February 28, 2023
    Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
  • Patent number: 11560417
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: January 24, 2023
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David Naor, Lora Eshkar-Sebban, Keren-Or Amar, Shmuel Cohen
  • Patent number: 11560433
    Abstract: Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: January 24, 2023
    Assignee: Albert Einstein College of Medicine
    Inventors: Paul S. Frenette, Sandra Pinho, Qiaozhi Wei, Sung Kyun Lee
  • Patent number: 11542325
    Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 3, 2023
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Patent number: 11505603
    Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: November 22, 2022
    Inventors: Kwang-Hoon Lee, June Hyung Lee, Na Rae Lee, Eunjeong Jeong, Young Bong Park, Nakho Chang, Eun-Jung Lee, Ki Hong Kim, Sunghyun Choi, Byung Hyun Choi, Ju Young Park, Moo Young Song, Jong-Seo Lee, Kyu-Tae Kim, Bong-Kook Ko
  • Patent number: 11492406
    Abstract: Methods and compositions comprising integrin ?8 antibodies are provided.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 8, 2022
    Assignee: The Regents of the University of California
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson
  • Patent number: 11485786
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Ilhan Celik, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • Patent number: 11479610
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: October 25, 2022
    Assignee: Cantargia AB
    Inventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
  • Patent number: 11472882
    Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 18, 2022
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.
    Inventors: Rudi Bao, Haiqing Hua, Suxia Liu, Fujun Zhang, Ting Wang